Considering that a nanobody can be used to determine HER2 status in breast cancer patients before trastuzumab treatment, Pruszynski et al. produced a radioiodine-bound HER2-specific nanobody (5F7GGC) and evaluated it for targeting HER2-expressing tumors. The gene discussed is ERBB2; the disease is breast cancer.